{"id":339975,"date":"2026-03-11T05:43:10","date_gmt":"2026-03-11T05:43:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/339975\/"},"modified":"2026-03-11T05:43:10","modified_gmt":"2026-03-11T05:43:10","slug":"the-role-and-possible-mechanism-of-intestinal-fungi-in-the-progression-of-chronic-liver-diseases","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/339975\/","title":{"rendered":"The role and possible mechanism of intestinal fungi in the progression of chronic liver diseases"},"content":{"rendered":"

Asrani, S. K., Devarbhavi, H., Eaton, J. & Kamath, P. S. Burden of liver diseases in the world. J. Hepatol. 70, 151\u2013171 (2019).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Shiina, S. et al. Liver disease trends in the Asia-Pacific region for the next 50 years. Clin. Mol. Hepatol. 31, 671\u2013684 (2025).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Gan, C. et al. Liver diseases: Epidemiology, causes, trends and predictions. Sig Transduct. Target Ther. 10, 33 (2025).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Zhao, Y. et al. Global burden of chronic liver disease and temporal trends: A population-based analysis from 1990 to 2021 with projections to 2050. Liver Int. 45, e70155 (2025).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Wang, R. et al. Gut microbiome, liver immunology, and liver diseases. Cell Mol. Immunol. 18, 4\u201317 (2021).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Wang, L., Cao, Z., Zhang, L., Li, J. & Lv, W. The role of gut microbiota in some liver diseases: From an immunological perspective. Front Immunol. 13, 923599 (2022).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59\u201365 (2010).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Zhang, L. L., Deng, W. H. & Wang, W. X. Characteristics and research progress on the role of intestinal fungi in chronic liver disease]. Zhonghua Gan Zang Bing. Za Zhi 30, 1285\u20131288 (2022).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Mohammadi, R., Morovati, H. & Safari, F. The human mycobiome: a critical yet understudied component of health and disease. Microbiology 171, 001631 (2025).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Zeng, S. & Schnabl, B. Roles for the mycobiome in liver disease. Liver Int 42, 729\u2013741 (2022).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Kong, H. H. & Segre, J. A. Cultivating fungal research. Science 368, 365\u2013366 (2020).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Zeng, S. & Schnabl, B. Gut mycobiome alterations and implications for liver diseases. PLoS Pathog. 20, e1012377 (2024).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Hartmann, P. & Schnabl, B. Fungal infections and the fungal microbiome in hepatobiliary disorders. J. Hepatol. 78, 836\u2013851 (2023).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Lang, S. et al. Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatology 71, 522\u2013538 (2020).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Demir, M. et al. The fecal mycobiome in non-alcoholic fatty liver disease. J. Hepatol. 76, 788\u2013799 (2022).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Yang, A.-M. et al. Intestinal fungi contribute to development of alcoholic liver disease. J. Clin. Invest 127, 2829\u20132841 (2017).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Chu, H. et al. The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. J. Hepatol. 72, 391\u2013400 (2020).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Patin, E. C., Thompson, A. & Orr, S. J. Pattern recognition receptors in fungal immunity. Semin Cell Dev. Biol. 89, 24\u201333 (2019).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Jensen, O., Trujillo, E., Hanson, L. & Ost, K. S. Controlling Candida: immune regulation of commensal fungi in the gut. Infect. Immun. 92, e0051623 (2024).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

You, N., Zhuo, L., Zhou, J., Song, Y. & Shi, J. The role of intestinal fungi and its metabolites in chronic liver diseases. Gut Liver 14, 291\u2013296 (2020).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Nash, A. K. et al. The gut mycobiome of the human microbiome project healthy cohort. Microbiome 5, 153 (2017).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Hallen-Adams, H. E., Kachman, S. D., Kim, J., Legge, R. M. & Mart\u00ednez, I. Fungi inhabiting the healthy human gastrointestinal tract: A diverse and dynamic community. Fungal Ecol. 15, 9\u201317 (2015).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Hsu, C. L. & Schnabl, B. The gut-liver axis and gut microbiota in health and liver disease. Nat. Rev. Microbiol 21, 719\u2013733 (2023).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Deng, X. et al. Composition, influencing factors, and effects on host nutrient metabolism of fungi in gastrointestinal tract of monogastric animals. Anim. (Basel) 15, 710 (2025).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Flint, H. J., Scott, K. P., Louis, P. & Duncan, S. H. The role of the gut microbiota in nutrition and health. Nat. Rev. Gastroenterol. Hepatol. 9, 577\u2013589 (2012).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Leonardi, I. et al. Mucosal fungi promote gut barrier function and social behavior via Type 17 immunity. Cell 185, 831\u2013846.e14 (2022).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Li, D. et al. Microbial biogeography and core microbiota of the rat digestive tract. Sci. Rep. 8, 45840 (2017).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Cui, L., Morris, A. & Ghedin, E. The human mycobiome in health and disease. Genome Med 5, 63 (2013).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Sun, Y. et al. Population-level configurations of gut mycobiome across 6 ethnicities in urban and rural China. Gastroenterology 160, 272\u2013286.e11 (2021).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Buttler, L. et al. Distinct clusters of bacterial and fungal microbiota in end-stage liver cirrhosis correlate with antibiotic treatment, intestinal barrier impairment, and systemic inflammation. Gut Microbes 17, 2487209 (2025).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Guo, Y. et al. A diet high in sugar and fat influences neurotransmitter metabolism and then affects brain function by altering the gut microbiota. Transl. Psychiatry 11, 328 (2021).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Chopyk, D. M. & Grakoui, A. Contribution of the intestinal microbiome and gut barrier to hepatic disorders. Gastroenterology 159, 849\u2013863 (2020).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Tripathi, A. et al. The gut-liver axis and the intersection with the microbiome. Nat. Rev. Gastroenterol. Hepatol. 15, 397\u2013411 (2018).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Zheng, Z. & Wang, B. The gut-liver axis in health and disease: The role of gut microbiota-derived signals in liver injury and regeneration. Front Immunol. 12, 775526 (2021).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Jiang, L. et al. The gut mycobiome: a novel player in chronic liver diseases. J. Gastroenterol. 56, 1\u201311 (2021).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Meroni, M., Longo, M. & Dongiovanni, P. Alcohol or gut microbiota: Who is the guilty? Int J. Mol. Sci. 20, 4568 (2019).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Asrani, S. K., Mellinger, J., Arab, J. P. & Shah, V. H. Reducing the global burden of alcohol-associated liver disease: A blueprint for action. Hepatology 73, 2039\u20132050 (2021).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Crabb, D. W., Im, G. Y., Szabo, G., Mellinger, J. L. & Lucey, M. R. Diagnosis and treatment of alcohol-associated liver diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology 71, 306\u2013333 (2020).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Bataller, R., Arab, J. P. & Shah, V. H. Alcohol-associated hepatitis. N. Engl. J. Med 387, 2436\u20132448 (2022).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Duki\u0107, M. et al. Alcohol, inflammation, and microbiota in alcoholic liver disease. Int J. Mol. Sci. 24, 3735 (2023).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Leclercq, S. et al. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc. Natl. Acad. Sci. USA 111, E4485\u2013E4493 (2014).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Gao, B., Ahmad, M. F., Nagy, L. E. & Tsukamoto, H. Inflammatory pathways in alcoholic steatohepatitis. J. Hepatol. 70, 249\u2013259 (2019).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Zeng, S. et al. Candida albicans-specific Th17 cell-mediated response contributes to alcohol-associated liver disease. Cell Host Microbe 31, 389\u2013404.e7 (2023).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Duan, Y. et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 575, 505\u2013511 (2019).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Hartmann, P. et al. Dynamic changes of the fungal microbiome in alcohol use disorder. Front Physiol. 12, 699253 (2021).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Teng, M. L. et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 29, S32\u2013S42 (2023).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Riazi, K. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 7, 851\u2013861 (2022).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Zhou, J. et al. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology 71, 1851\u20131864 (2020).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Fang, J. et al. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications. Front Cell Infect. Microbiol 12, 997018 (2022).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Loomba, R. & Adams, L. A. The 20% rule of NASH progression: The natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology 70, 1885\u20131888 (2019).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Younossi, Z. M., Kalligeros, M. & Henry, L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin. Mol. Hepatol. 31, S32\u2013S50 (2025).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

You, N. et al. Fecal fungi dysbiosis in nonalcoholic fatty liver disease. Obes. (Silver Spring) 29, 350\u2013358 (2021).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Viebahn, G. et al. Fungal signature differentiates alcohol-associated liver disease from nonalcoholic fatty liver disease. Gut Microbes 16, 2307586 (2024).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Scarlata, G. G. M. et al. Gut microbiota changes in metabolic dysfunction-associated steatohepatitis and inflammatory bowel disease: Common pathogenic features. Curr. Issues Mol. Biol. 47, 847 (2025).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Zhou, S. et al. A symbiotic filamentous gut fungus ameliorates MASH via a secondary metabolite-CerS6-ceramide axis. Science 388, eadp5540 (2025).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Liu, Y. T., Li, Y. Q. & Wang, Y. Z. Protective effect of Saccharomyces boulardii against intestinal mucosal barrier injury in rats with nonalcoholic fatty liver disease]. Zhonghua Gan Zang Bing. Za Zhi 24, 921\u2013926 (2016).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Cooper, J. et al. Incidence and prevalence of primary sclerosing cholangitis: A meta-analysis of population-based studies. Inflamm. Bowel Dis. 30, 2019\u20132026 (2024).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Olfatifar, M. et al. The epidemiological trends and projected future of primary sclerosing cholangitis by 2040: An updated meta-analysis and modeling study. PLoS One 20, e0322479 (2025).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Boonstra, K. et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 58, 2045\u20132055 (2013).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Dyson, J. K., Beuers, U., Jones, D. E. J., Lohse, A. W. & Hudson, M. Primary sclerosing cholangitis. Lancet 391, 2547\u20132559 (2018).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Sirpal, S. & Chandok, N. Primary sclerosing cholangitis: Diagnostic and management challenges. Clin. Exp. Gastroenterol. 10, 265\u2013273 (2017).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Shah, A., Macdonald, G. A., Morrison, M. & Holtmann, G. Targeting the gut microbiome as a treatment for primary sclerosing cholangitis: A conceptional framework. Am. J. Gastroenterol. 115, 814\u2013822 (2020).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Lv, L.-X. et al. Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis. Environ. Microbiol 18, 2272\u20132286 (2016).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Tang, R. et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut 67, 534\u2013541 (2018).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Furukawa, M. et al. Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis. Hepatol. Res 50, 840\u2013852 (2020).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Abe, K. et al. Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease. PLoS One 13, e0198757 (2018).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Wang, Y., Zhao, Z., Lu, H., Zhang, J. & Huang, F. Fungal infection involvement in primary biliary cirrhosis: A review of 2 cases. Exp. Ther. Med 13, 489\u2013494 (2017).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Samonakis, D. N., Chatzicostas, C., Vardas, E., Roussomoustakaki, M. & Kouroumalis, E. A. Increased incidence of fungal infections in advanced primary biliary cirrhosis. J. Clin. Gastroenterol. 36, 369 (2003).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Muratori, P. et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin. Exp. Immunol. 132, 473\u2013476 (2003).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Lee, M. J. A review of liver fibrosis and cirrhosis regression. J. Pathol. Transl. Med 57, 189\u2013195 (2023).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Opulente, D. A. et al. Genomic factors shape carbon and nitrogen metabolic niche breadth across Saccharomycotina yeasts. Science 384, eadj4503 (2024).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Kulaksiz, H. et al. Biliary candida infections in primary sclerosing cholangitis. J. Hepatol. 45, 711\u2013716 (2006).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Rudolph, G. et al. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J. Hepatol. 51, 149\u2013155 (2009).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Bacher, P. et al. Human anti-fungal Th17 immunity and pathology rely on cross-reactivity against candida albicans. Cell 176, 1340\u20131355.e15 (2019).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Katt, J. et al. Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis. Hepatology 58, 1084\u20131093 (2013).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Harada, K. et al. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin. Exp. Immunol. 157, 261\u2013270 (2009).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Lan, R. Y. Z. et al. Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J. Autoimmun. 32, 43\u201351 (2009).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Albillos, A., de Gottardi, A. & Rescigno, M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J. Hepatol. 72, 558\u2013577 (2020).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Trebicka, J., Reiberger, T. & Laleman, W. Gut-liver axis links portal hypertension to acute-on-chronic liver failure. Visc. Med. 34, 270\u2013275 (2018).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Tandon, P. & Garcia-Tsao, G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 28, 26\u201342 (2008).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Righi, E. Management of bacterial and fungal infections in end stage liver disease and liver transplantation: Current options and future directions. World J. Gastroenterol. 24, 4311\u20134329 (2018).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Lahmer, T. et al. Fungal \u2018colonisation\u2019 is associated with increased mortality in medical intensive care unit patients with liver cirrhosis. Mycopathologia 179, 63\u201371 (2015).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Bajaj, J. S. et al. Fungal dysbiosis in cirrhosis. Gut 67, 1146\u20131154 (2018).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Perlin, C. M., Longo, L., Keingeski, M. B., Picon, R. V. & \u00c1lvares-da-Silva, M. R. Gut mycobiota changes in liver diseases: A systematic review. Med Mycol. 61, myad071 (2023).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Chen, Y. et al. Correlation between gastrointestinal fungi and varying degrees of chronic hepatitis B virus infection. Diagn. Microbiol Infect. Dis. 70, 492\u2013498 (2011).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Park, W. B. et al. Spontaneous cryptococcal peritonitis in patients with liver cirrhosis. Am. J. Med 119, 169\u2013171 (2006).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Gravito-Soares, M., Gravito-Soares, E., Lopes, S., Ribeiro, G. & Figueiredo, P. Spontaneous fungal peritonitis: a rare but severe complication of liver cirrhosis. Eur. J. Gastroenterol. Hepatol. 29, 1010\u20131016 (2017).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Bartoletti, M. et al. Epidemiology and outcomes of bloodstream infection in patients with cirrhosis. J. Hepatol. 61, 51\u201358 (2014).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Bajaj, J. S. et al. Prediction of fungal infection development and their impact on survival using the NACSELD cohort. Am. J. Gastroenterol. 113, 556\u2013563 (2018).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Papp, M. et al. Presence of anti-microbial antibodies in liver cirrhosis-a tell-tale sign of compromised immunity? PLoS One 5, e12957 (2010).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Hwang, S. Y. et al. Spontaneous fungal peritonitis: A severe complication in patients with advanced liver cirrhosis. Eur. J. Clin. Microbiol Infect. Dis. 33, 259\u2013264 (2014).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Lahmer, T., Brandl, A., Rasch, S., Schmid, R. M. & Huber, W. Fungal peritonitis: Underestimated disease in critically ill patients with liver cirrhosis and spontaneous peritonitis. PLoS One 11, e0158389 (2016).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 7, 6 (2021).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Dutta, R. & Mahato, R. I. Recent advances in hepatocellular carcinoma therapy. Pharm. Ther. 173, 106\u2013117 (2017).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Yang, J. D. & Heimbach, J. K. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ 371, m3544 (2020).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Bertuccio, P. et al. Global trends and predictions in hepatocellular carcinoma mortality. J. Hepatol. 67, 302\u2013309 (2017).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Xie, Y. et al. GULP1, a multifaceted diagnostic biomarker and potential therapeutic target in hepatocellular carcinoma: Editorial on \u2018GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma. Clin. Mol. Hepatol. 32, 413\u2013415 (2026).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Han, J. E. et al. Uncovering the MET-TRIB3-FOXO1 axis: A novel target in MET-driven hepatocellular carcinoma: Editorial on \u2018MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation. Clin. Mol. Hepatol. 32, 436\u2013438 (2026).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Kew, M. C. Aflatoxins as a cause of hepatocellular carcinoma. J. Gastrointestin Liver Dis. 22, 305\u2013310 (2013).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Jiang, S. et al. Longitudinal gut fungal alterations and potential fungal biomarkers for the progression of primary liver disease. Sci. China Life Sci. 67, 1183\u20131198 (2024).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Zhang, L. et al. Characterization of the intestinal fungal microbiome in patients with hepatocellular carcinoma. J. Transl. Med 21, 126 (2023).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Liu, Z. et al. Intestinal Candida albicans Promotes Hepatocarcinogenesis by Up-Regulating NLRP6. Front Microbiol 13, 812771 (2022).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Fairfield, B. & Schnabl, B. Gut dysbiosis as a driver in alcohol-induced liver injury. JHEP Rep. 3, 100220 (2021).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Zeng, S. et al. Malassezia restricta promotes alcohol-induced liver injury. Hepatol. Commun. 7, e0029 (2023).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Ulusan, M. et al. Saccharomyces boulardii mitigates fructose-induced non-alcoholic fatty liver in rats. Med. (Kaunas.) 60, 1713 (2024).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Yu, L. et al. Saccharomyces boulardii administration changes gut microbiota and attenuates D-galactosamine-induced liver injury. Sci. Rep. 7, 1359 (2017).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Abarenkov, K. et al. The UNITE database for molecular identification and taxonomic communication of fungi and other eukaryotes: Sequences, taxa and classifications reconsidered. Nucleic Acids Res. 52, D791\u2013D797 (2024).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Fosso, B. et al. ITSoneDB: a specialized ITS1 database for amplicon-based metagenomic characterization of environmental fungal communities. EMBnet. J. 18, 90 (2012).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Suhr, M. J. & Hallen-Adams, H. E. The human gut mycobiome: pitfalls and potentials-a mycologist\u2019s perspective. Mycologia 107, 1057\u20131073 (2015).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Doan, H. T. et al. Candida tropicalis alters barrier permeability and claudin-1 organization in intestinal epithelial cells. J. Physiol. Investig. 68, 67 (2025).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Morelli, M. & Queiroz, K. Breaking Barriers: Candidalysin disrupts epithelial integrity and induces inflammation in a gut-on-chip model. Toxins (Basel) 17, 89 (2025).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Allert, S. et al. Candida albicans-induced epithelial damage mediates translocation through intestinal barriers. mBio 9, https:\/\/doi.org\/10.1128\/mbio.00915-18<\/a> (2018).<\/p>\n

\u00d6zdirik, B. & Schnabl, B. Microbial players in primary sclerosing cholangitis: Current evidence and concepts. Cell Mol. Gastroenterol. Hepatol. 17, 423\u2013438 (2024).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Romani, L. Immunity to fungal infections. Nat. Rev. Immunol. 11, 275\u2013288 (2011).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Brown, G. D. & Gordon, S. Fungal beta-glucans and mammalian immunity. Immunity 19, 311\u2013315 (2003).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Plato, A. et al. Pattern recognition receptors in antifungal immunity. Semin Immunopathol. 37, 97\u2013106 (2015).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Theel, E. S. & Doern, C. D. \u03b2-D-glucan testing is important for diagnosis of invasive fungal infections. J. Clin. Microbiol 51, 3478\u20133483 (2013).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Kondori, N., Edebo, L. & Mattsby-Baltzer, I. Circulating beta (1-3) glucan and immunoglobulin G subclass antibodies to Candida albicans cell wall antigens in patients with systemic candidiasis. Clin. Diagn. Lab Immunol. 11, 344\u2013350 (2004).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Seki, E. & Brenner, D. A. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 48, 322\u2013335 (2008).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Chen, L. et al. The role of gut bacteria and fungi in alcohol-associated liver disease. Front Med (Lausanne) 9, 840752 (2022).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Iliev, I. D. & Leonardi, I. Fungal dysbiosis: Immunity and interactions at mucosal barriers. Nat. Rev. Immunol. 17, 635\u2013646 (2017).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Drummond, R. A. et al. CARD9+ microglia promote antifungal immunity via IL-1\u03b2- and CXCL1-mediated neutrophil recruitment. Nat. Immunol. 20, 559\u2013570 (2019).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Mirea, A.-M. et al. Increased proteinase 3 and neutrophil elastase plasma concentrations are associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes. Mol. Med 25, 16 (2019).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Ma, D. W. et al. Innate immune system in the pathogenesis of non-alcoholic fatty liver disease. Nutrients 15, 2068 (2023).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Mbaye, B. et al. Endogenous ethanol and triglyceride production by gut pichia kudriavzevii, candida albicans and candida glabrata yeasts in non-alcoholic steatohepatitis. Cells 11, 3390 (2022).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Mims, T. S. et al. The gut mycobiome of healthy mice is shaped by the environment and correlates with metabolic outcomes in response to diet. Commun. Biol. 4, 281 (2021).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Sudun, W. ulijideligen, Arakawa, K., Miyamoto, M. & Miyamoto, T. Interaction between lactic acid bacteria and yeasts in airag, an alcoholic fermented milk. Anim. Sci. J. 84, 66\u201374 (2013).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Bivin, W. S. & Heinen, B. N. Production of ethanol from infant food formulas by common yeasts. J. Appl Bacteriol. 58, 355\u2013357 (1985).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Bayoumy, A. B., Mulder, C. J. J., Mol, J. J. & Tushuizen, M. E. Gut fermentation syndrome: A systematic review of case reports. U. Eur. Gastroenterol. J. 9, 332\u2013342 (2021).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Gr\u00f3zer, Z. et al. Candida parapsilosis produces prostaglandins from exogenous arachidonic acid and OLE2 is not required for their synthesis. Virulence 6, 85\u201392 (2015).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Noverr, M. C., Phare, S. M., Toews, G. B., Coffey, M. J. & Huffnagle, G. B. Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins. Infect. Immun. 69, 2957\u20132963 (2001).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Sun, S. et al. Therapeutic manipulation of gut microbiota by polysaccharides of Wolfiporia cocos reveals the contribution of the gut fungi-induced PGE2 to alcoholic hepatic steatosis. Gut Microbes 12, 1830693 (2020).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Wang, W., Zhong, X. & Guo, J. Role of 2\u2011series prostaglandins in the pathogenesis of type 2 diabetes mellitus and non\u2011alcoholic fatty liver disease (Review). Int J. Mol. Med 47, 114 (2021).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Henkel, J. et al. Augmented liver inflammation in a microsomal prostaglandin E synthase 1 (mPGES-1)-deficient diet-induced mouse NASH model. Sci. Rep. 8, 16127 (2018).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Smeekens, S. P. et al. The Candida Th17 response is dependent on mannan- and beta-glucan-induced prostaglandin E2. Int Immunol. 22, 889\u2013895 (2010).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Gagliardi, M. C. et al. Endogenous PGE2 promotes the induction of human Th17 responses by fungal \u00df-glucan. J. Leukoc. Biol. 88, 947\u2013954 (2010).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Lafdil, F., Miller, A. M., Ki, S. H. & Gao, B. Th17 cells and their associated cytokines in liver diseases. Cell Mol. Immunol. 7, 250\u2013254 (2010).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Kasper, L. et al. The fungal peptide toxin Candidalysin activates the NLRP3 inflammasome and causes cytolysis in mononuclear phagocytes. Nat. Commun. 9, 4260 (2018).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Mridha, A. R. et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J. Hepatol. 66, 1037\u20131046 (2017).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

He, K. et al. Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development. Oncotarget 8, 37657\u201337672 (2017).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Magnussen, A. & Parsi, M. A. Aflatoxins, hepatocellular carcinoma and public health. World J. Gastroenterol. 19, 1508\u20131512 (2013).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Hamid, A. S., Tesfamariam, I. G., Zhang, Y. & Zhang, Z. G. Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention. Oncol. Lett. 5, 1087\u20131092 (2013).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Kew, M. C. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int 23, 405\u2013409 (2003).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Heisel, T. et al. High-fat diet changes fungal microbiomes and interkingdom relationships in the murine gut. mSphere 2, e00351-17 (2017).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Fern\u00e1ndez de Ullivarri, M., Arbulu, S., Garcia-Gutierrez, E. & Cotter, P. D. Antifungal peptides as therapeutic agents. Front Cell Infect. Microbiol 10, 105 (2020).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Kombrink, A. et al. Induction of antibacterial proteins and peptides in the coprophilous mushroom Coprinopsis cinerea in response to bacteria. ISME J. 13, 588\u2013602 (2019).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Shao, T.-Y. et al. Commensal candida albicans positively calibrates systemic Th17 immunological responses. Cell Host Microbe 25, 404\u2013417.e6 (2019).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Chen, Y.-H. et al. Rewilding of laboratory mice enhances granulopoiesis and immunity through intestinal fungal colonization. Sci. Immunol. 8, eadd6910 (2023).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Garc\u00eda, C. et al. The human gut microbial metabolome modulates fungal growth via the TOR signaling pathway. mSphere 2, e00555-17 (2017).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Alonso-Roman, R. et al. Lactobacillus rhamnosus colonisation antagonizes Candida albicans by forcing metabolic adaptations that compromise pathogenicity. Nat. Commun. 13, 3192 (2022).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Noverr, M. C. & Huffnagle, G. B. Regulation of Candida albicans morphogenesis by fatty acid metabolites. Infect. Immun. 72, 6206\u20136210 (2004).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Lynch, A. S. & Robertson, G. T. Bacterial and fungal biofilm infections. Annu Rev. Med 59, 415\u2013428 (2008).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

van Leeuwen, P. T. et al. Interspecies Interactions between Clostridium difficile and Candida albicans. mSphere 1, e00187\u201316 (2016).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Chen, L. et al. Modulating phenylalanine metabolism by L. acidophilus alleviates alcohol-related liver disease through enhancing intestinal barrier function. Cell Biosci. 13, 24 (2023).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Wang, W., Gao, X., Niu, W., Yin, J. & He, K. Targeting Metabolism: Innovative Therapies for MASLD Unveiled. Int J. Mol. Sci. 26, 4077 (2025).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Kim, H. Y. & Rinella, M. E. Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment. Clin. Mol. Hepatol. 31, 753\u2013770 (2025).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Szajewska, H., Konarska, Z. & Ko\u0142odziej, M. Probiotic bacterial and fungal strains: Claims with evidence. Dig. Dis. 34, 251\u2013259 (2016).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Duman, D. G. et al. Saccharomyces boulardii ameliorates clarithromycin- and methotrexate-induced intestinal and hepatic injury in rats. Br. J. Nutr. 110, 493\u2013499 (2013).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Li, M., Zhu, L., Xie, A. & Yuan, J. Oral administration of Saccharomyces boulardii ameliorates carbon tetrachloride-induced liver fibrosis in rats via reducing intestinal permeability and modulating gut microbial composition. Inflammation 38, 170\u2013179 (2015).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Bourrie, B. C. T., Willing, B. P. & Cotter, P. D. The microbiota and health promoting characteristics of the fermented beverage kefir. Front Microbiol 7, 647 (2016).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Gonz\u00e1lez-Orozco, B. D., Garc\u00eda-Cano, I., Jim\u00e9nez-Flores, R. & Alv\u00e1rez, V. B. Invited review: Milk kefir microbiota-Direct and indirect antimicrobial effects. J. Dairy Sci. 105, 3703\u20133715 (2022).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Eyre, D. W. et al. A candida auris outbreak and its control in an intensive care setting. N. Engl. J. Med 379, 1322\u20131331 (2018).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Brown, G. D. et al. Hidden killers: human fungal infections. Sci. Transl. Med 4, 165rv13 (2012).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Robbins, N., Wright, G. D. & Cowen, L. E. Antifungal drugs: the current armamentarium and development of new agents. Microbiol. Spectr. 4, 903\u2013922 (2016).<\/p>\n

Huang, H. et al. The mycobiome as integral part of the gut microbiome: crucial role of symbiotic fungi in health and disease. Gut Microbes 16, 2440111 (2024).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Bao, L., Zhang, Y., Zhang, G., Jiang, D. & Yan, D. Abnormal proliferation of gut mycobiota contributes to the aggravation of Type 2 diabetes. Commun. Biol. 6, 226 (2023).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Li, X. et al. Response to fungal dysbiosis by gut-resident CX3CR1+ mononuclear phagocytes aggravates allergic airway disease. Cell Host Microbe 24, 847\u2013856.e4 (2018).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Wheeler, M. L. et al. Immunological consequences of intestinal fungal dysbiosis. Cell Host Microbe 19, 865\u2013873 (2016).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Gadour, E. & Kotb, A. Systematic review of antifungal-induced acute liver failure. Cureus 13, e18940 (2021).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Spernovasilis, N. & Kofteridis, D. P. Pre-existing liver disease and toxicity of antifungals. J. Fungi (Basel) 4, 133 (2018).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Craven, L. et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: A randomized control trial. Am. J. Gastroenterol. 115, 1055\u20131065 (2020).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Allegretti, J. R. et al. Fecal microbiota transplantation in patients with primary sclerosing cholangitis: A pilot clinical trial. Am. J. Gastroenterol. 114, 1071\u20131079 (2019).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Chauhan, A. et al. Fecal microbiota transplantation in hepatitis B e antigen-positive chronic Hepatitis B patients: A pilot study. Dig. Dis. Sci. 66, 873\u2013880 (2021).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Acharya, S. & Thirunavukkarasu, C. Gut microbiome and cancer: From cancer development to therapeutics with a special focus on hepatocellular carcinoma. Front Biosci. (Landmark Ed.) 29, 67 (2024).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Bajaj, J. S. et al. Fecal microbial transplant capsules are safe in hepatic encephalopathy: A phase 1, randomized, placebo-controlled trial. Hepatology 70, 1690\u20131703 (2019).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Philips, C. A., Ahamed, R., Rajesh, S., Abduljaleel, J. K. P. & Augustine, P. Long-term outcomes of stool transplant in alcohol-associated hepatitis-analysis of clinical outcomes, relapse, gut microbiota and comparisons with standard care. J. Clin. Exp. Hepatol. 12, 1124\u20131132 (2022).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Philips, C. A. et al. Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: A pilot study. Clin. Gastroenterol. Hepatol. 15, 600\u2013602 (2017).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Sharma, A. et al. Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial. Hepatol. Int 16, 433\u2013446 (2022).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Xue, L., Deng, Z., Luo, W., He, X. & Chen, Y. Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: A randomized clinical trial. Front Cell Infect. Microbiol 12, 759306 (2022).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Yadegar, A. et al. Beneficial effects of fecal microbiota transplantation in recurrent Clostridioides difficile infection. Cell Host Microbe 31, 695\u2013711 (2023).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Sheng, L. et al. Hepatic inflammation caused by dysregulated bile acid synthesis is reversible by butyrate supplementation. J. Pathol. 243, 431\u2013441 (2017).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Zuo, T. et al. Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection. Nat. Commun. 9, 3663 (2018).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Danne, C., Rolhion, N. & Sokol, H. Recipient factors in faecal microbiota transplantation: one stool does not fit all. Nat. Rev. Gastroenterol. Hepatol. 18, 503\u2013513 (2021).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

DeFilipp, Z. et al. Drug-Resistant E. coli bacteremia transmitted by fecal microbiota transplant. N. Engl. J. Med. 381, 2043\u20132050 (2019).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Bajaj, J. S., Ng, S. C. & Schnabl, B. Promises of microbiome-based therapies. J. Hepatol. 76, 1379\u20131391 (2022).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Hoffmann, C. et al. Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS One 8, e66019 (2013).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Costabile, A. et al. Whole-grain wheat breakfast cereal has a prebiotic effect on the human gut microbiota: A double-blind, placebo-controlled, crossover study. Br. J. Nutr. 99, 110\u2013120 (2008).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Carvalho-Wells, A. L. et al. Determination of the in vivo prebiotic potential of a maize-based whole grain breakfast cereal: A human feeding study. Br. J. Nutr. 104, 1353\u20131356 (2010).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

R\u00fchlemann, M. C. et al. Gut mycobiome of primary sclerosing cholangitis patients is characterised by an increase of Trichocladium griseum and Candida species. Gut 69, 1890\u20131892 (2020).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Lemoinne, S. et al. Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. Gut 69, 92\u2013102 (2020).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n","protected":false},"excerpt":{"rendered":"Asrani, S. K., Devarbhavi, H., Eaton, J. & Kamath, P. S. Burden of liver diseases in the world.…\n","protected":false},"author":2,"featured_media":339976,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[1733,1707,1437,103,61,60,2137,15087,62862,6834,2746],"class_list":{"0":"post-339975","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-diseases","9":"tag-gastroenterology","10":"tag-general","11":"tag-health","12":"tag-ie","13":"tag-ireland","14":"tag-life-sciences","15":"tag-medical-microbiology","16":"tag-microbial-ecology","17":"tag-microbial-genetics-and-genomics","18":"tag-microbiology"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/339975","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=339975"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/339975\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/339976"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=339975"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=339975"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=339975"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}